-The Hindu     Drug patents are designed to create profits that enable more research on diseases affecting millions. But in practice, they have often generated super profits for big pharma companies while erecting access barriers for the poor. The Novartis case spotlights much that is wrong with the system. The rejection of the Novartis petition challenging one of the most progressive tenets of the Indian Patents Act (1970), as amended in 2005 by...

-Live Mint Tariffs reach at least Rs.4 per unit in many states, finds analysis, amid efforts to bail out state discoms Indian domestic consumers in 16 states are paying at least `4 per unit for power and in some cases even more, according to an analysis, thus giving the lie to the long-held axiom that raising tariffs is nearly impossible in India given the political compulsions. The finding also shows conclusively that...

-The Economic Times MUMBAI: India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that...

-The Indian Express Report finds govt did not recover dues of Rs 750 cr from distributors. At a time when the opposition BJP plans to intensify protests against power tariff in Delhi, the Comptroller and Auditor General (CAG) of India's report for the 2011-12 fiscal has slammed the Delhi government for not recovering dues to the tune of Rs 750 crore from private distribution companies. The report, tabled on Tuesday in the Delhi...

-The Economic Times To ensure access to healthcare for all, India must harness innovation in discovering drugs, in developing therapeutics and in delivering affordable healthcare. It is in the light of these facts that one should evaluate the impact of the Indian Supreme Court's ruling in the case involving patent protection for Novartis AG's cancer drug, Glivec. Glivec was the first-of-its-kind cancer drug for leukaemia patients with patent protection in nearly 40...